Brand and Pipeline Highlights in the Cushing’s Syndrome Market during Q1 2026 New Campaigns from Gilead and ViiV in the Q1 2026 Antiretrovirals (HIV) SnapShot

Atumelnant was positioned as a first-in-class MC2R antagonist with strong Phase 2 data, highlighting differentiation and blockbuster potential in CAH.

Clofutriben updates emphasized Phase 2b progress and its novel HSD-1 mechanism in T2D, with improvements in cortisol and glycemic markers and continued pipeline expansion.

Isturisa messaging focused on rapid cortisol normalization, efficacy, and practical HCP use, supported by clinical and real-world data.

Korlym emphasized cortisol control and diagnostic awareness, combining HCP-focused clinical application with patient storytelling and support resources.